Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. World most cancers statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2024;74:229–63. https://doi.org/10.3322/caac.21834.
Wilson JF. Liver most cancers on the rise. Ann Intern Med. 2005;142:1029–32. https://doi.org/10.7326/0003-4819-142-12_part_1-200506210-00024.
Peng J, Lü M, Peng Y, Tang X. World incidence of major liver most cancers by etiology amongst youngsters, adolescents, and younger adults. J Hepatol. 2023;79:e92–4. https://doi.org/10.1016/j.jhep.2023.02.019.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. World most cancers statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA Most cancers J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.
Kim BH, Park JW. Epidemiology of liver most cancers in South Korea. Clin Mol Hepatol. 2018;24:1–9. https://doi.org/10.3350/cmh.2017.0112.
Chen JG, Zhang SW. Liver most cancers epidemic in China: previous, current and future. Semin Most cancers Biol. 2011;21:59–69. https://doi.org/10.1016/j.semcancer.2010.11.002.
Duan XY, Zhang L, Fan JG, Qiao L. NAFLD results in liver most cancers: do we’ve ample proof? Most cancers Lett. 2014;345:230–4. https://doi.org/10.1016/j.canlet.2013.07.033.
Li G, Yao Q, Liu P, Zhang H, Liu Y, Li S, et al. Important roles and scientific views of RNA methylation in most cancers. MedComm. 2020;2024(5): e559. https://doi.org/10.1002/mco2.559.
Huang PS, Wang LY, Wang YW, Tsai MM, Lin TK, Liao CJ, et al. Analysis and software of drug resistance by biomarkers within the scientific remedy of liver most cancers. Cells. 2023. https://doi.org/10.3390/cells12060869.
Nikolaou Okay, Sarris M, Talianidis I. Molecular pathways: the advanced roles of irritation pathways within the growth and remedy of liver most cancers. Clin Most cancers Res. 2013;19:2810–6. https://doi.org/10.1158/1078-0432.Ccr-12-1961.
He Y, Shi M, Wu X, Ma J, Ng KT, Xia Q, et al. Mutational signature evaluation reveals widespread contribution of pyrrolizidine alkaloid publicity to human liver most cancers. Hepatology. 2021;74:264–80. https://doi.org/10.1002/hep.31723.
Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver most cancers: approaching a personalised care. J Hepatol. 2015;62:S144–56. https://doi.org/10.1016/j.jhep.2015.02.007.
Fu X, Zhang Y, Luo Q, Ju Y, Music G. Concentrating on the mechano-microenvironment and liver most cancers stem cells: a promising therapeutic technique for liver most cancers. Most cancers Biol Med. 2023;20:816–29. https://doi.org/10.20892/j.issn.2095-3941.2023.0229.
Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune problems and most cancers. Sign Transduct Goal Ther. 2023;8:204. https://doi.org/10.1038/s41392-023-01468-7.
Hao L, Li S, Deng J, Li N, Yu F, Jiang Z, et al. The present standing and way forward for PD-L1 in liver most cancers. Entrance Immunol. 2023;14:1323581. https://doi.org/10.3389/fimmu.2023.1323581.
Zheng Y, Wang S, Cai J, Ke A, Fan J. The progress of immune checkpoint remedy in major liver most cancers. Biochim Biophys Acta Rev Most cancers. 2021;1876: 188638. https://doi.org/10.1016/j.bbcan.2021.188638.
Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver most cancers and potential remedy approaches. Biochim Biophys Acta Rev Most cancers. 2020;1873: 188314. https://doi.org/10.1016/j.bbcan.2019.188314.
Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic panorama in major and metastatic liver most cancers. Nat Rev Most cancers. 2021;21:541–57. https://doi.org/10.1038/s41568-021-00383-9.
de Lope CR, Tremosini S, Forner A, Reig M, Bruix J. Administration of HCC. J Hepatol. 2012;56(Suppl 1):S75-87. https://doi.org/10.1016/s0168-8278(12)60009-9.
Li L, Wang H. Heterogeneity of liver most cancers and personalised remedy. Most cancers Lett. 2016;379:191–7. https://doi.org/10.1016/j.canlet.2015.07.018.
Kensler TW, Qian GS, Chen JG, Groopman JD. Translational methods for most cancers prevention in liver. Nat Rev Most cancers. 2003;3:321–9. https://doi.org/10.1038/nrc1076.
Macek B, Forchhammer Okay, Hardouin J, Weber-Ban E, Grangeasse C, Mijakovic I. Protein post-translational modifications in micro organism. Nat Rev Microbiol. 2019;17:651–64. https://doi.org/10.1038/s41579-019-0243-0.
Vu LD, Gevaert Okay, De Smet I. Protein language: post-translational modifications speaking to one another. Development Plant Sci. 2018;23:1068–80. https://doi.org/10.1016/j.tplants.2018.09.004.
Bradley D. The evolution of post-translational modifications. Curr Opin Genet Dev. 2022;76: 101956. https://doi.org/10.1016/j.gde.2022.101956.
Shu F, Xiao H, Li QN, Ren XS, Liu ZG, Hu BW, et al. Epigenetic and post-translational modifications in autophagy: organic features and therapeutic targets. Sign Transduct Goal Ther. 2023;8:32. https://doi.org/10.1038/s41392-022-01300-8.
Lee JM, Hammarén HM, Savitski MM, Baek SH. Management of protein stability by post-translational modifications. Nat Commun. 2023;14:201. https://doi.org/10.1038/s41467-023-35795-8.
DeShields RW. Gnathological issues of a controversial nature. Ohio Dent J. 1977;51:23–7.
Tolsma TO, Hansen JC. Submit-translational modifications and chromatin dynamics. Essays Biochem. 2019;63:89–96. https://doi.org/10.1042/ebc20180067.
Patwardhan P, Miller WT. Processive phosphorylation: mechanism and organic significance. Cell Sign. 2007;19:2218–26. https://doi.org/10.1016/j.cellsig.2007.06.006.
Galinier A, Deutscher J. Refined regulation of transcriptional components by the bacterial phosphoenolpyruvate: sugar phosphotransferase system. J Mol Biol. 2017;429:773–89. https://doi.org/10.1016/j.jmb.2017.02.006.
Huang B, Zhao Z, Zhao Y, Huang S. Protein arginine phosphorylation in organisms. Int J Biol Macromol. 2021;171:414–22. https://doi.org/10.1016/j.ijbiomac.2021.01.015.
Zhou T, Wang M, Cheng A, Yang Q, Tian B, Wu Y, et al. Regulation of alphaherpesvirus protein through post-translational phosphorylation. Vet Res. 2022;53:93. https://doi.org/10.1186/s13567-022-01115-z.
Derouiche A, Cousin C, Mijakovic I. Protein phosphorylation from the attitude of methods biology. Curr Opin Biotechnol. 2012;23:585–90. https://doi.org/10.1016/j.copbio.2011.11.008.
Gil J, Ramírez-Torres A, Encarnación-Guevara S. Lysine acetylation and most cancers: a proteomics perspective. J Proteom. 2017;150:297–309. https://doi.org/10.1016/j.jprot.2016.10.003.
King CM, Glowinski IB. Acetylation, deacetylation and acyltransfer. Environ Well being Perspect. 1983;49:43–50. https://doi.org/10.1289/ehp.834943.
Baeza J, Smallegan MJ, Denu JM. Mechanisms and dynamics of protein acetylation in mitochondria. Development Biochem Sci. 2016;41:231–44. https://doi.org/10.1016/j.tibs.2015.12.006.
Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo j. 2000;19:1176–9. https://doi.org/10.1093/emboj/19.6.1176.
Polevoda B, Sherman F. Methylation of proteins concerned in translation. Mol Microbiol. 2007;65:590–606. https://doi.org/10.1111/j.1365-2958.2007.05831.x.
Stallcup MR. Function of protein methylation in chromatin reworking and transcriptional regulation. Oncogene. 2001;20:3014–20. https://doi.org/10.1038/sj.onc.1204325.
Nicholson TB, Chen T, Richard S. The physiological and pathophysiological position of PRMT1-mediated protein arginine methylation. Pharmacol Res. 2009;60:466–74. https://doi.org/10.1016/j.phrs.2009.07.006.
Eichler J. Protein glycosylation. Curr Biol. 2019;29:R229–31. https://doi.org/10.1016/j.cub.2019.01.003.
Rudd PM, Dwek RA. Glycosylation: heterogeneity and the 3D construction of proteins. Crit Rev Biochem Mol Biol. 1997;32:1–100. https://doi.org/10.3109/10409239709085144.
Schjoldager KT, Narimatsu Y, Joshi HJ, Clausen H. World view of human protein glycosylation pathways and features. Nat Rev Mol Cell Biol. 2020;21:729–49. https://doi.org/10.1038/s41580-020-00294-x.
Xu M, Yang A, Xia J, Jiang J, Liu CF, Ye Z, et al. Protein glycosylation in urine as a biomarker of illnesses. Transl Res. 2023;253:95–107. https://doi.org/10.1016/j.trsl.2022.08.001.
Costa J, Hayes C, Lisacek F. Protein glycosylation and glycoinformatics for novel biomarker discovery in neurodegenerative illnesses. Ageing Res Rev. 2023;89: 101991. https://doi.org/10.1016/j.arr.2023.101991.
Xiang T, Zhao S, Wu Y, Li L, Fu P, Ma L. Novel post-translational modifications within the kidneys for human well being and illnesses. Life Sci. 2022;311: 121188. https://doi.org/10.1016/j.lfs.2022.121188.
Pienkowski T, Kowalczyk T, Cysewski D, Kretowski A, Ciborowski M. Glioma and post-translational modifications: a posh relationship. Biochim Biophys Acta Rev Most cancers. 2023;1878: 189009. https://doi.org/10.1016/j.bbcan.2023.189009.
Hermann J, Schurgers L, Jankowski V. Identification and characterization of post-translational modifications: scientific implications. Mol Asps Med. 2022;86: 101066. https://doi.org/10.1016/j.mam.2022.101066.
Jarrold J, Davies CC. PRMTs and arginine methylation: most cancers’s best-kept secret? Development Mol Med. 2019;25:993–1009. https://doi.org/10.1016/j.molmed.2019.05.007.
Zhang J, Xun M, Li C, Chen Y. The O-GlcNAcylation and its promotion to hepatocellular carcinoma. Biochim Biophys Acta Rev Most cancers. 2022;1877: 188806. https://doi.org/10.1016/j.bbcan.2022.188806.
Hu M, Zhang R, Yang J, Zhao C, Liu W, Huang Y, et al. The position of N-glycosylation modification within the pathogenesis of liver most cancers. Cell Demise Dis. 2023;14:222. https://doi.org/10.1038/s41419-023-05733-z.
Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition via epigenetic and post-translational modifications. Mol Most cancers. 2016;15:18. https://doi.org/10.1186/s12943-016-0502-x.
Liu X, Zhang Y, Wang Y, Yang M, Hong F, Yang S. Protein phosphorylation in most cancers: position of nitric oxide signaling pathway. Biomolecules. 2021. https://doi.org/10.3390/biom11071009.
Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in most cancers and irritation. Development Biochem Sci. 2005;30:43–52. https://doi.org/10.1016/j.tibs.2004.11.009.
Ayyadevara S, Balasubramaniam M, Kakraba S, Alla R, Mehta JL, Shmookler Reis RJ. Aspirin-mediated acetylation protects towards a number of neurodegenerative pathologies by impeding protein aggregation. Antioxid Redox Sign. 2017;27:1383–96. https://doi.org/10.1089/ars.2016.6978.
Hyun Okay, Jeon J, Park Okay, Kim J. Writing, erasing and studying histone lysine methylations. Exp Mol Med. 2017;49: e324. https://doi.org/10.1038/emm.2017.11.
Zheng Okay, Chen S, Ren Z, Wang Y. Protein arginine methylation in viral an infection and antiviral immunity. Int J Biol Sci. 2023;19:5292–318. https://doi.org/10.7150/ijbs.89498.
Stowell SR, Ju T, Cummings RD. Protein glycosylation in most cancers. Annu Rev Pathol. 2015;10:473–510. https://doi.org/10.1146/annurev-pathol-012414-040438.
Wang Y, Chen H. Protein glycosylation alterations in hepatocellular carcinoma: operate and scientific implications. Oncogene. 2023;42:1970–9. https://doi.org/10.1038/s41388-023-02702-w.
Bangarh R, Khatana C, Kaur S, Sharma A, Kaushal A, Siwal SS, et al. Aberrant protein glycosylation: Implications on analysis and Immunotherapy. Biotechnol Adv. 2023;66: 108149. https://doi.org/10.1016/j.biotechadv.2023.108149.
Wang YW, Zuo JC, Chen C, Li XH. Submit-translational modifications and immune responses in liver most cancers. Entrance Immunol. 2023;14:1230465. https://doi.org/10.3389/fimmu.2023.1230465.
Mowen KA, David M. Unconventional post-translational modifications in immunological signaling. Nat Immunol. 2014;15:512–20. https://doi.org/10.1038/ni.2873.
Nagel T, Klaus F, Ibanez IG, Wege H, Lohse A, Meyer B. Quick and facile evaluation of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver most cancers and liver cirrhosis. Anal Bioanal Chem. 2018;410:7965–77. https://doi.org/10.1007/s00216-018-1418-7.
Ren QN, Zhang H, Solar CY, Zhou YF, Yang XF, Lengthy JW, et al. Phosphorylation of androgen receptor by mTORC1 promotes liver steatosis and tumorigenesis. Hepatology. 2022;75:1123–38. https://doi.org/10.1002/hep.32120.
Mestareehi A, Abu-Farsakh N. Affect of protein phosphatase expressions on the prognosis of hepatocellular carcinoma sufferers. ACS Omega. 2024;9:10299–331. https://doi.org/10.1021/acsomega.3c07787.
Nishimagi A, Kobayashi M, Sugimoto Okay, Kofunato Y, Sato N, Haga J, et al. Aberrant phosphorylation of human LRH1 at serine 510 is predictable of hepatocellular carcinoma recurrence. Clin Exp Med. 2023;23:4985–95. https://doi.org/10.1007/s10238-023-01098-x.
Zhang Y, Lao W, Yang Okay, Kong X, Li Y, Yu X, et al. SUV39H1 is a novel biomarker concentrating on oxidative phosphorylation in hepatitis B virus-associated hepatocellular carcinoma. BMC Most cancers. 2023;23:1159. https://doi.org/10.1186/s12885-023-11633-4.
Wu Okay, Yan M, Liu T, Wang Z, Duan Y, Xia Y, et al. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 via a moonlighting operate. Nat Cell Biol. 2023;25:714–25. https://doi.org/10.1038/s41556-023-01133-9.
Zhan M, Ding Y, Huang S, Liu Y, Xiao J, Yu H, et al. Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to advertise liver most cancers chemoresistance by stabilizing dihydroorotate dehydrogenase. Nat Commun. 2023;14:3123. https://doi.org/10.1038/s41467-023-38753-6.
Xu D, Wang Z, Xia Y, Shao F, Xia W, Wei Y, et al. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature. 2020;580:530–5. https://doi.org/10.1038/s41586-020-2183-2.
Feng J, Lu H, Ma W, Tian W, Lu Z, Yang H, et al. Genome-wide CRISPR display identifies artificial lethality between DOCK1 inhibition and metformin in liver most cancers. Protein Cell. 2022;13:825–41. https://doi.org/10.1007/s13238-022-00906-6.
Wei CY, Zhu MX, Zhang PF, Huang XY, Wan JK, Yao XZ, et al. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. J Hepatol. 2022;77:163–76. https://doi.org/10.1016/j.jhep.2022.02.019.
Jiang N, Li W, Jiang S, Xie M, Liu R. Acetylation in pathogenesis: revealing rising mechanisms and therapeutic prospects. Biomed Pharmacother. 2023;167: 115519. https://doi.org/10.1016/j.biopha.2023.115519.
Wu Z, Guan KL. Acetyl-CoA, protein acetylation, and liver most cancers. Mol Cell. 2022;82:4196–8. https://doi.org/10.1016/j.molcel.2022.10.015.
Wang LT, Wang SN, Chiou SS, Liu KY, Chai CY, Chiang CM, et al. TIP60-dependent acetylation of the SPZ1-TWIST advanced promotes epithelial-mesenchymal transition and metastasis in liver most cancers. Oncogene. 2019;38:518–32. https://doi.org/10.1038/s41388-018-0457-z.
Jing Z, Gao J, Li J, Niu F, Tian L, Nan P, et al. Acetylation-induced PCK isoenzyme transition promotes metabolic adaption of liver most cancers to systemic remedy. Most cancers Lett. 2021;519:46–62. https://doi.org/10.1016/j.canlet.2021.06.016.
Gu L, Zhu Y, Lin X, Tan X, Lu B, Li Y. Stabilization of FASN by ACAT1-mediated GNPAT acetylation promotes lipid metabolism and hepatocarcinogenesis. Oncogene. 2020;39:2437–49. https://doi.org/10.1038/s41388-020-1156-0.
Lin M, He J, Zhang X, Solar X, Dong W, Zhang R, et al. Concentrating on fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma. J Clin Make investments. 2023. https://doi.org/10.1172/jci164528.
Hu H, Zhu W, Qin J, Chen M, Gong L, Li L, et al. Acetylation of PGK1 promotes liver most cancers cell proliferation and tumorigenesis. Hepatology. 2017;65:515–28. https://doi.org/10.1002/hep.28887.
Zhang T, Cui Y, Wu Y, Meng J, Han L, Zhang J, et al. Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma. Clin Transl Med. 2022;12: e852. https://doi.org/10.1002/ctm2.852.
Zhou Y, Jia Okay, Wang S, Li Z, Li Y, Lu S, et al. Malignant development of liver most cancers progenitors requires lysine acetyltransferase 7-acetylated and cytoplasm-translocated G protein GαS. Hepatology. 2023;77:1106–21. https://doi.org/10.1002/hep.32487.
Bi L, Ren Y, Feng M, Meng P, Wang Q, Chen W, et al. HDAC11 regulates glycolysis via the LKB1/AMPK signaling pathway to keep up hepatocellular carcinoma stemness. Most cancers Res. 2021;81:2015–28. https://doi.org/10.1158/0008-5472.Can-20-3044.
Cai LY, Chen SJ, Xiao SH, Solar QJ, Ding CH, Zheng BN, et al. Concentrating on p300/CBP attenuates hepatocellular carcinoma development via epigenetic regulation of metabolism. Most cancers Res. 2021;81:860–72. https://doi.org/10.1158/0008-5472.Can-20-1323.
Xia H, Hui KM. Emergence of aspirin as a promising chemopreventive and chemotherapeutic agent for liver most cancers. Cell Demise Dis. 2017;8: e3112. https://doi.org/10.1038/cddis.2017.513.
Nio Okay, Yamashita T, Kaneko S. The evolving idea of liver most cancers stem cells. Mol Most cancers. 2017;16:4. https://doi.org/10.1186/s12943-016-0572-9.
Cheng Z, Li X, Ding J. Traits of liver most cancers stem cells and scientific correlations. Most cancers Lett. 2016;379:230–8. https://doi.org/10.1016/j.canlet.2015.07.041.
Xue M, Dong L, Zhang H, Li Y, Qiu Okay, Zhao Z, et al. METTL16 promotes liver most cancers stem cell self-renewal through controlling ribosome biogenesis and mRNA translation. J Hematol Oncol. 2024;17:7. https://doi.org/10.1186/s13045-024-01526-9.
Solar JH, Luo Q, Liu LL, Music GB. Liver most cancers stem cell markers: development and therapeutic implications. World J Gastroenterol. 2016;22:3547–57. https://doi.org/10.3748/wjg.v22.i13.3547.
Wang F, Gao Y, Xue S, Zhao L, Jiang H, Zhang T, et al. SCARB2 drives hepatocellular carcinoma tumor initiating cells through enhanced MYC transcriptional exercise. Nat Commun. 2023;14:5917. https://doi.org/10.1038/s41467-023-41593-z.
Raposo AE, Piller SC. Protein arginine methylation: an rising regulator of the cell cycle. Cell Div. 2018;13:3. https://doi.org/10.1186/s13008-018-0036-2.
Zhao J, Adams A, Roberts B, O’Neil M, Vittal A, Schmitt T, et al. Protein arginine methyl transferase 1- and Jumonji C domain-containing protein 6-dependent arginine methylation regulate hepatocyte nuclear issue 4 alpha expression and hepatocyte proliferation in mice. Hepatology. 2018;67:1109–26. https://doi.org/10.1002/hep.29587.
Lei Y, Han P, Chen Y, Wang H, Wang S, Wang M, et al. Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma progress by enhancing arginine methylation of lactate dehydrogenase A. Clin Transl Med. 2022;12: e686. https://doi.org/10.1002/ctm2.686.
Shi Y, Niu Y, Yuan Y, Li Okay, Zhong C, Qiu Z, et al. PRMT3-mediated arginine methylation of IGF2BP1 promotes oxaliplatin resistance in liver most cancers. Nat Commun. 2023;14:1932. https://doi.org/10.1038/s41467-023-37542-5.
Li Q, Zhang L, Yang Q, Li M, Pan X, Xu J, et al. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and-independent manners. Cell Metab. 2023;35:912-27.e7. https://doi.org/10.1016/j.cmet.2023.03.017.
Wang Okay, Luo L, Fu S, Wang M, Wang Z, Dong L, et al. PHGDH arginine methylation by PRMT1 promotes serine synthesis and represents a therapeutic vulnerability in hepatocellular carcinoma. Nat Commun. 2023;14:1011. https://doi.org/10.1038/s41467-023-36708-5.
Deng W, Ai J, Zhang W, Zhou Z, Li M, Yan L, et al. Arginine methylation of HSPA8 by PRMT9 inhibits ferroptosis to speed up hepatitis B virus-associated hepatocellular carcinoma development. J Transl Med. 2023;21:625. https://doi.org/10.1186/s12967-023-04408-9.
Thng DKH, Hooi L, Toh CCM, Lim JJ, Rajagopalan D, Syariff IQC, et al. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver most cancers. Mol Oncol. 2023;17:2275–94. https://doi.org/10.1002/1878-0261.13417.
Liu Z, Wang Q, Mao J, Wang Okay, Fang Z, Miao QR, et al. Comparative proteomic evaluation of protein methylation supplies perception into the resistance of hepatocellular carcinoma to 5-fluorouracil. J Proteom. 2020;219: 103738. https://doi.org/10.1016/j.jprot.2020.103738.
Liu Q, Chen Okay, Liu Z, Huang Y, Zhao R, Wei L, et al. BORIS up-regulates OCT4 through histone methylation to advertise most cancers stem cell-like properties in human liver most cancers cells. Most cancers Lett. 2017;403:165–74. https://doi.org/10.1016/j.canlet.2017.06.017.
Guo M, Yao Z, Jiang C, Songyang Z, Gan L, Xiong Y. Three-dimensional and single-cell sequencing of liver most cancers reveals complete host-virus interactions in HBV an infection. Entrance Immunol. 2023;14:1161522. https://doi.org/10.3389/fimmu.2023.1161522.
You H, Zhang N, Yu T, Ma L, Li Q, Wang X, et al. Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 through TRIM25 to facilitate hepatocarcinogenesis. Br J Most cancers. 2023;128:992–1004. https://doi.org/10.1038/s41416-022-02115-8.
Wang Y, Zhao M, Zhao L, Geng Y, Li G, Chen L, et al. HBx-induced HSPA8 stimulates HBV replication and suppresses ferroptosis to assist liver most cancers development. Most cancers Res. 2023;83:1048–61. https://doi.org/10.1158/0008-5472.Can-22-3169.
Yang L, Zou T, Chen Y, Zhao Y, Wu X, Li M, et al. Hepatitis B virus X protein mediated epigenetic alterations within the pathogenesis of hepatocellular carcinoma. Hepatol Int. 2022;16:741–54. https://doi.org/10.1007/s12072-022-10351-6.
Liu S, Koh SS, Lee CG. Hepatitis B virus X protein and hepatocarcinogenesis. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17060940.
Chen J, Li X, Ge C, Min J, Wang F. The multifaceted position of ferroptosis in liver illness. Cell Demise Differ. 2022;29:467–80. https://doi.org/10.1038/s41418-022-00941-0.
Wang W, Lu Okay, Jiang X, Wei Q, Zhu L, Wang X, et al. Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in major liver most cancers. J Exp Clin Most cancers Res. 2023;42:142. https://doi.org/10.1186/s13046-023-02720-2.
Huang Y, Wang S, Ke A, Guo Okay. Ferroptosis and its interplay with tumor immune microenvironment in liver most cancers. Biochim Biophys Acta Rev Most cancers. 2023;1878: 188848. https://doi.org/10.1016/j.bbcan.2022.188848.
Yang L, Tian S, Zheng X, Zhang M, Zhou X, Shang Y, et al. N6-methyladenosine RNA methylation in liver illnesses: from mechanism to remedy. J Gastroenterol. 2023;58:718–33. https://doi.org/10.1007/s00535-023-02008-4.
Liu Y, Feng W, Wang Y, Wu B. Crosstalk between protein post-translational modifications and section separation. Cell Commun Sign. 2024;22:110. https://doi.org/10.1186/s12964-023-01380-1.
Im H, Baek HJ, Yang E, Kim Okay, Oh SK, Lee JS, et al. ROS inhibits RORα degradation by reducing its arginine methylation in liver most cancers. Most cancers Sci. 2023;114:187–200. https://doi.org/10.1111/cas.15595.
Blomme B, Van Steenkiste C, Callewaert N, Van Vlierberghe H. Alteration of protein glycosylation in liver illnesses. J Hepatol. 2009;50:592–603. https://doi.org/10.1016/j.jhep.2008.12.010.
Zhang X, Liu H, Wang H, Zhao R, Lu Q, Liu Y, et al. B3galt5 deficiency attenuates hepatocellular carcinoma by suppressing mTOR/p70s6k-mediated glycolysis. Cell Mol Life Sci. 2022;80:8. https://doi.org/10.1007/s00018-022-04601-x.
Cheng H, Wang S, Gao D, Yu Okay, Chen H, Huang Y, et al. Nucleotide sugar transporter SLC35A2 is concerned in selling hepatocellular carcinoma metastasis by regulating mobile glycosylation. Cell Oncol. 2023;46:283–97. https://doi.org/10.1007/s13402-022-00749-7.
Nguyen AT, Chia J, Ros M, Hui KM, Saltel F, Bard F. Organelle particular O-glycosylation drives MMP14 activation, tumor progress, and metastasis. Most cancers Cell. 2017;32:639-53.e6. https://doi.org/10.1016/j.ccell.2017.10.001.
Li J, Liu X, Peng B, Feng T, Zhou W, Meng L, et al. O-GlcNAc has crosstalk with ADP-ribosylation through PARG. J Biol Chem. 2023;299: 105354. https://doi.org/10.1016/j.jbc.2023.105354.
Zhou P, Chang WY, Gong DA, Xia J, Chen W, Huang LY, et al. Excessive dietary fructose promotes hepatocellular carcinoma development by enhancing O-GlcNAcylation through microbiota-derived acetate. Cell Metab. 2023;35:1961-75.e6. https://doi.org/10.1016/j.cmet.2023.09.009.
Xiang J, Chen C, Liu R, Gou D, Chang L, Deng H, et al. Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma progress upon glucose deprivation. J Clin Make investments. 2021. https://doi.org/10.1172/jci144703.
Zou X, Lu J, Deng Y, Liu Q, Yan X, Cui Y, et al. ST6GAL1 inhibits metastasis of hepatocellular carcinoma through modulating sialylation of MCAM on cell floor. Oncogene. 2023;42:516–29. https://doi.org/10.1038/s41388-022-02571-9.
Liu L, Pan Y, Zhao C, Huang P, Chen X, Rao L. Boosting checkpoint immunotherapy with biomaterials. ACS Nano. 2023;17:3225–58. https://doi.org/10.1021/acsnano.2c11691.
Khalilov R, Bakishzade A, Nasibova A. Future prospects of biomaterials in nanomedicine. Adv Biol Earth Sci. 2023. https://doi.org/10.62476/abes.9s5.
Rosic G, Selakovic D, Omarova S. Most cancers signaling, cell/gene remedy, analysis and position of nanobiomaterials. Adv Biol Earth Sci. 2024. https://doi.org/10.62476/abes9s11.
Huseynov E, Khalilov R, Mohamed AJ. Novel nanomaterials for hepatobiliary illnesses remedy and future views. Adv Biol Earth Sci. 2024. https://doi.org/10.2476/abes9s81.
Salahshour P. Nanobiomaterials/bioinks based mostly scaffolds in 3d bioprinting for tissue engineering and synthetic human organs. Adv Biol Earth Sci. 2024;9:97–104. https://doi.org/10.2476/abes9s97.
Erdil N. Heart problems, signaling, gene/cell remedy and superior nanobiomaterials. Adv Biol Earth Sci. 2024;9:58–80.
Xu M, Yang L, Lin Y, Lu Y, Bi X, Jiang T, et al. Rising nanobiotechnology for exact theranostics of hepatocellular carcinoma. J Nanobiotechnology. 2022;20:427. https://doi.org/10.1186/s12951-022-01615-2.
Chi X, Liu Okay, Luo X, Yin Z, Lin H, Gao J. Current advances of nanomedicines for liver most cancers remedy. J Mater Chem B. 2020;8:3747–71. https://doi.org/10.1039/c9tb02871d.
Shao D, Li J, Zheng X, Pan Y, Wang Z, Zhang M, et al. Janus “nano-bullets” for magnetic concentrating on liver most cancers chemotherapy. Biomaterials. 2016;100:118–33. https://doi.org/10.1016/j.biomaterials.2016.05.030.
Han Q, Du L, Zhu L, Yu D. Assessment of the applying of twin drug supply nanotheranostic brokers within the analysis and remedy of liver most cancers. Molecules. 2023. https://doi.org/10.3390/molecules28207004.
Wu S, Fan Okay, Yang Q, Chen Z, Hou Y, Zou Y, et al. Sensible nanoparticles and microbeads for interventional embolization remedy of liver most cancers: cutting-edge. J Nanobiotechnology. 2023;21:42. https://doi.org/10.1186/s12951-023-01804-7.
Kong FH, Ye QF, Miao XY, Liu X, Huang SQ, Xiong L, et al. Present standing of sorafenib nanoparticle supply methods within the remedy of hepatocellular carcinoma. Theranostics. 2021;11:5464–90. https://doi.org/10.7150/thno.54822.
